Aquestive Therapeutics, Inc. (NASDAQ:AQST – Get Free Report) was the recipient of a large growth in short interest during the month of April. As of April 15th, there was short interest totalling 4,010,000 shares, a growth of 76.7% from the March 31st total of 2,270,000 shares. Based on an average trading volume of 2,450,000 shares, the days-to-cover ratio is currently 1.6 days.
Aquestive Therapeutics Stock Up 3.6 %
NASDAQ:AQST traded up $0.14 during trading hours on Friday, hitting $4.07. 2,986,647 shares of the company were exchanged, compared to its average volume of 2,312,568. Aquestive Therapeutics has a 52-week low of $1.19 and a 52-week high of $6.23. The company’s 50 day moving average price is $4.17 and its 200-day moving average price is $2.81.
Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.08) by ($0.04). The business had revenue of $13.21 million for the quarter, compared to analyst estimates of $11.79 million. Analysts anticipate that Aquestive Therapeutics will post -0.36 EPS for the current year.
Insider Transactions at Aquestive Therapeutics
Institutional Trading of Aquestive Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of the business. PFG Investments LLC acquired a new position in shares of Aquestive Therapeutics in the 1st quarter valued at $204,000. Essex Investment Management Co. LLC acquired a new position in shares of Aquestive Therapeutics in the 4th quarter valued at $1,709,000. Jump Financial LLC acquired a new position in shares of Aquestive Therapeutics in the 4th quarter valued at $60,000. Legato Capital Management LLC acquired a new position in Aquestive Therapeutics during the fourth quarter worth $688,000. Finally, Armistice Capital LLC raised its position in Aquestive Therapeutics by 314.5% during the third quarter. Armistice Capital LLC now owns 4,800,000 shares of the company’s stock worth $7,344,000 after acquiring an additional 3,642,000 shares during the period. 32.45% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of research analysts have commented on the stock. Piper Sandler assumed coverage on shares of Aquestive Therapeutics in a research report on Thursday, April 11th. They set an “overweight” rating and a $10.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of Aquestive Therapeutics in a research report on Friday, April 5th. Raymond James assumed coverage on shares of Aquestive Therapeutics in a research report on Thursday, March 28th. They issued an “outperform” rating and a $7.00 price objective on the stock. Finally, JMP Securities lifted their price objective on shares of Aquestive Therapeutics from $8.00 to $10.00 and gave the stock an “outperform” rating in a research report on Friday, March 15th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Aquestive Therapeutics presently has an average rating of “Buy” and a consensus price target of $8.00.
Read Our Latest Analysis on Aquestive Therapeutics
Aquestive Therapeutics Company Profile
Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.
See Also
- Five stocks we like better than Aquestive Therapeutics
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 4/22 – 4/26
- Following Congress Stock Trades
- 3 Stocks Leading the U.S. Agriculture Comeback
- Earnings Per Share Calculator: How to Calculate EPS
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.